regardless of positive clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from managed care entities. The insurers are often building obstacles to reimbursement, including steep cost restrictions and approval processes that limit consumer access. Industry i